The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.
作者信息
Subbiah V, Solit D B, Chan T A, Kurzrock R
机构信息
Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
出版信息
Ann Oncol. 2020 Sep;31(9):1115-1118. doi: 10.1016/j.annonc.2020.07.002. Epub 2020 Aug 5.
PMID:32771306
Abstract
摘要
Zotero 插件